

Medtronic launches new technology in India to treat brain aneurysms

01 June 2022 | News

Pipeline Vantage Embolization Device with Shield Technology has been launched

India [Medtronic](#), a wholly owned subsidiary of Medtronic plc, has announced the launch of CE marked fourth-generation flow diverter, Pipeline Vantage with Shield Technology for endovascular treatment of brain aneurysms.

Pipeline Vantage with Shield Technology is a new flow diverter with enhanced design features to both the delivery system and implant. These features allow physicians to deliver, deploy and treat brain aneurysms, intracranial aneurysms with greater ease and reliability while providing a scaffold that promotes growth of cells in the inner lining of the target blood vessel.

Every year in India, around 76,000 to 200,000 cases of aneurysmal subarachnoid hemorrhage (SAH) are reported to have occurred. Since brain aneurysms are most prevalent between 35 and 60 years of age and about 40% of the ruptures are fatal, a great number of disability adjusted life years are lost. Advances in flow diversion over the last 10 years has helped to significantly reduce the rate of aneurysm rupture.

“Since 2013, we’ve been disrupting aneurysm treatment, advancing the practice and raising the standard of care in India. Medtronic is consistently committed to bringing innovative technologies to India to improve quality of life for patients and ease of doing procedure for surgeons. Our newest Pipeline Vantage Embolization Device comes with a one-of-its-kind warranty for device efficacy. With this, we hope to boost patient assurance on our offerings while encouraging flow diversion as a form of therapy for aneurysms,” said Rahul Arora, Director of Neurosciences Therapies, Medtronic India.